drugset / Trial / NCT00784966
Islet After Kidney Transplant for Type 1 Diabetes
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine if prolonged administration of the anti TNF (tumor necrosis factor)-Alpha agent etanercept is associated with enhanced graft survival in patients undergoing islet after kidney transplantation.
Timeline
- Start
- 2011-08
- Primary completion
- 2015-09
- Completion
- 2017-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Etanercept | Protein / enzyme biologic | 25 mg | Intravenous |